Wednesday, July 8, 2026

pharma · Asthma · Multiple Sclerosis · TEVA

Teva Pharma

Teva Biotech is a pharma organization headquartered in TEL AVIV, DE. It trades on NYSE under ticker TEVA. Primary therapeutic focus areas include Asthma, Multiple Sclerosis, Pain, Crohn's Disease, Seasonal Allergic Rhini

10 Dornierstr., Ulm, Donau, 89079, DE, TEL AVIV HQ
126 Employees
Public company Type
TEVA · NYSE Ticker
Company details
Clinical program

reslizumab

Phase 3 · small molecule · Eosinophilic Esophagitis

reslizumab for Eosinophilic Esophagitis is a Phase 3 program (small_molecule) at Teva Pharma GmbH with 2 ClinicalTrials.gov record(s).

← All Teva Pharma GmbH projects Phase 3 small molecule completed

Internal code Res-5-0004

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Teva Pharma GmbH
Phase
Phase 3
Modality
small_molecule
Indication
Eosinophilic Esophagitis
Status
completed
Trials
2